Clinical Trial Update: Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with or without everolimus in recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: GOG Foundation | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-02